Sutro Biopharma (STRO) Corporate presentation summary

Platform and technology

• Proprietary cell-free platform enables site-specific conjugation for uniform, stable ADCs, enhancing safety and efficacy.

• Platform allows flexibility in linker-payload combinations and scalability from discovery to commercial scale.

• Optimized antibodies, linkers, and payloads expand the therapeutic window, reducing toxicity and maximizing efficacy.

• Industry-leading ADC exposure achieved in non-human primates, supporting better pharmacokinetics and reduced systemic toxicity.

Pipeline and development programs

• Advancing three INDs in three years: STRO-004 (TF-targeting), STRO-006 (ITGB6-targeting), and STRO-227 (PTK7 dual-payload).

• STRO-004 Phase 1 trial ongoing in solid tumors, with initial data expected mid-2026.

• STRO-006 IND submission planned for 2026, targeting integrin beta 6 in multiple solid tumors.

• STRO-227, a dual-payload ADC targeting PTK7, anticipates IND filing in 2026/2027.

• Runway extends into at least mid-2027, supported by expected milestone payments.

Clinical and preclinical data

• STRO-004 shows 50x preclinical exposure over approved TF ADC, with reduced bleeding risk and favorable tolerability.

• Demonstrated promising anti-tumor activity in multiple TF-expressing cancer models, with high disease control and response rates.

• STRO-006 exhibits superior activity and duration of response in ITGB6-expressing preclinical models compared to competitors.

• Dual-payload ADCs overcome resistance and drive tumor regression in preclinical models, with tolerability benchmarks matching single-payload ADCs.